# AcceleRET-Lung (NCT04222972)

> A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04222972
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Hoffmann-La Roche
- Conditions: RET-fusion Non Small Cell Lung Cancer; Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Disease; Carcinoma, Bronchogenic; Bronchial Diseases; Head and Neck Neoplasms; Adenocarcinoma; Carcinoma; Neoplasms by Histologic Type; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue
- Interventions: Pralsetinib; Carboplatin; Cisplatin; Pemetrexed; Pembrolizumab; Gemcitabine; Paclitaxel; Nab-Paclitaxel
- Enrollment: 223
- Primary outcome: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS)

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=acceleret-lung-nct04222972